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1. Introduction 
Administration of the dopamine antagonist, dom- 
peridone [ 1,2] stimulates TSH secretion in man [3]. 
Since dopamine suppresses both in vivo and in vitro 
basal and stimulated TSH secretion [4-81 and there 
is evidence that dopamine and domperidone do not 
cross the blood-brain barrier [ 1,2,9], this stimulatory 
effect of domperidone has been attributed to antago- 
nism of dopaminergic inhibition of anterior pituitary 
TSH secretion [ 31. As yet, however, a direct effect of 
domperidone on the thyrotroph has not been dis- 
counted. 
Here, we demonstrate a direct stimulatory effect 
of domperidone on basal TSH secretion from rat ante- 
rior pituitary cells in culture, in the absence of dopa- 
mine. Dopamine alone did not modify basal TSH secre- 
tion, but did antagonise the TSH stimulatory effect 
of domperidone. In contrast, domperidone had no 
effect on basal prolactin secretion, but did antagonise 
dopaminergic inhibition of prolaction secretion. 
These results suggest a differential sensitivity of 
lactotrophs and thyrotrophs to dopamine inhibition, 
and indicate that the in vivo TSH stimulatory effect 
of domperidone may not be entirely due to any dopa- 
minergic antagonist properties of the drug. 
2, Materials and methods 
2.1. Preparation of rat anterior pituitary cell cultures 
Female Wistar rats (1 SO-220 g) were decapitated; 
the anterior pituitaries were removed and placed 
immediately in culture medium (Eagle’s minimal 
essential medium containing 10% foetal calf serum 
(Gibco) 100 U/ml penicillin, 100 Mg/ml streptomycin 
(Glaxo) and 2.5 pg/ml fungizone (Squibb), buffered 
with 20 mM Hepes (Hopkins and Williams) and 20 mM 
sodium bicarbonate. 
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The pooled anterior pituitaries were cut into 
-1 mm3 pieces, washed with phosphobuffered saline 
(pH 7.3) (Oxoid) and dispersed by 6 consecutive 
20 min incubations at 37’C in 20ml phosphobuffered 
saline containing 0 .125% trypsin (Wellcome Reagents). 
Dispersed cells were aspirated and recovered by cen- 
trifugation (200 X g; 5 min). The resulting cells pellets 
were washed with 1 ml culture medium, pooled, recen- 
trifuged and dispersed in 20 ml culture medium. Cells 
were counted using a haemocytometer and diluted 
with culture medium to give 2 X 10’ cells/ml medium. 
CelI viability, determined by the trypan blue exclu- 
sion method, was >95%. 2.5 X 10’ cells were added 
to glass tubes (Labco SlOOWC) and incubated at 37’C 
for 4 days to allow cell attachment prior to use in 
experiments. 
2.2. Experimental procedures 
Domperidone (Janssen Pharmaceuticals) was ini- 
tially dissolved in 0.01 M HCl and subsequently diluted 
with ascorbate containing medium. The final maxi- 
mum concentration of HCl used (5 X 10s6 M) did not 
modify prolactin or TSH secretion. Dopamine HCl 
(Arnar-Stone Labs) and thyrotrophin-releasing hor- 
mone (Roche) were diluted with ascorbate containing 
medium. 
Prior to experiments, cells were washed with 2 ml 
culture medium. Experiments were performed at 37°C 
in closed tubes, using 2 ml culture medium conta&ing 
10 4 M ascorbic acid and appropriate drugs. A mini- 
mum of 5 cultures were used/treatment group. After 
a 4 h incubation, the culture medium was decanted 
and assayed for TSH and prolactin using reagents pro- 
vided by Dr A. F. Parlow of the National Pituitary 
Agency. Prolactin secretion was expressed as ng 
NIAMDD-rat Prl-RP-2 and TSH as ng NIAMDD-rat 
TSH-RP-1. Data were analysed using the Student’s 
‘t’-test . 
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3. Results a Basal 
Incubation of rat anterior pituitary cells with 
2.4 X 1 O-‘-2.4 X 1 O-’ M domperidone for 4 h signif- 
icantly C~J < 0.02) increased TSH secretion. The same 
effect was observed in a second experiment (fig.l), in 
which 5 X 10e7 M dopamine decreased the stimulation 
producedby2.4X 10e9Mand2.4X 10W8M@<0.01 
andp < 0.05, respectively) but not 2.4 X 10m7 M 
domperidone. Similar results were obtained using a 
lower dose of dopamine (1 X 1 Oe7 M). Dopamine had 
no effect on basal TSH secretion. 
a 1 x 10s7M Dcqamine 
6co 
1 5 x 10e7M Dcpamine 
Domperidone had no effect on basal prolactin 
secretion at the concentrations tested (4.8 X 10m8 M 
and 2.4 X IO-’ M) but both doses blocked the inhibi- 
tion produced by 5 X 10e7 M dopamine (fig.%). Thy- 
rotrophin-releasing hormone (1.5 X 1 Om7 M) signifi- 
cantly stimulated TSH and prolactin release in all 
experiments (JJ < 0.001). 
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4. Discussion 
Domperidone increases serum TSH and prolactin 
levels in man, and is believed to act by blocking the 
peripheral action of dopamine [3]. Our results;show- 
ing domperidone blocks the inhibitory effect of dopa- 
mine on prolactin secretion by rat anterior pituitary 
cells, are consistent with this view. However, the paral- 
lel demonstration that domperidone, when added 
alone, stimulates basal TSH secretion in vitro, suggests 
that this drug can act other than by dopamine block- 
ade in respect of TSH secretion. The possibility that 
endogenous dopamine was present in the cultures 
would appear to be discounted, since domperidone 
had no effect on basal PRL secretion. Moreover, in 
these experiments we did not find an effect of dopa- 
mine on basal TSH secretion, although in vitro sup- 
pression has been reported [8]. Lack of dopamine sup- 
pression of TSH almost certainly relates to the use of 
lower concentrations in our studies. Nevertheless, 
these same doses significantly suppressed PRL secre- 
tion and are higher than levels reported to be present 
in rat hypophyseal portal blood [ 1 O-l 31. Thus these 
results suggest a differential in the sensitivity of lacto- 
trophs and thyrotrophs to dopamine. 
Fig.1. Effect of dopamine on basal and domperidone-stimu- 
lated TSH secretion from rat anterior pituitary cells in cul- 
ture: *p < 0.05; ***p < O.Ol;domperidone YS domperidone- 
and dopamine-treated cultures. 
m Basal 
5 x 10m7,v, Dopamine 
m 1.5 x 10-7M TRH 
The observed inhibition of domperidone-stimulated 
TSH secretion by dopamine may represent dopamin- 
ergic inhibition of stimulated TSH secretion, rather 
than any specific domperidone-dopamine interac- 
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Fig.2. Effect of dopamine and domperidone on prolactiu secre- 
tion from rat anterior pituitary cells in culture : * *p < 0.02 YS 
ascorbic acid-treated cultures. 
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tion at dopamine receptors. Inhibition of basal TSH 
secretion by dopamine was shown [ 81 using cells pre- 
cultured for 24 h in dibutryl cyclic AMP, a stimulator 
of TSH release. 
In conclusion, these results demonstrate that dom- 
peridone alone stimulates basal TSH secretion in vitro 
and suggest caution in attributing the in vivo TSH 
stimulator-y effect of domperidone solely to dopamine 
antagonism. The results also indicate that dopamine 
would appear to be of lesser importance in the regula- 
tion of TSH than prolactin. 
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